Invasive pulmonary aspergillosis in oncological setting with use of newer vascular endothelial growth factor receptor inhibitor

Muzamil, Javvid; Guru, Faisal R; Hakim, Ansar; Nabi, Firdousa

doi:10.4103/2225-6482.179232

Cited by 3 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study on acute leukemia and hematopoietic stem cell transplantation (HSCT) patients, the overall observed mortality rate was 15.3% (all causes), and according to the EORTC/MSG classification of IA cases, the mortality was 36% in possible IA, 41.1% in probable IA, and 100% in proven IA cases (48). Recently, in hematological malignancy patients, the 4-month observed mortality rate due to IA was found to be 30% (49).…”

mentioning

confidence: 99%

Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India

Dabas

Xess

Bakshi

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

This prospective study shows that the rate of azole-resistant (ARAF) in an immunocompromised Indian patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This low rate supports the continued use of voriconazole as the first line of treatment. However, the ARAF isolates from India in this study exhibited three kinds of unreported mutations, of which two were at hot spots, G54R and P216L, while one was at codon Y431C.

show abstract

mentioning

confidence: 99%

Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India

Dabas

Xess

Bakshi

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…In a previous study employing an immunosuppression murine model of IPA, treatment with recombinant VEGF prolonged survival, although it did not reduce fungal burden ( 68 ). Additionally, to date, several cases of IPA in cancer patients treated with the new anti-cancer therapeutics bevacizumab, a VEGF inhibitor, or pazopanib, a VEGF receptor inhibitor, have been reported ( 69 , 70 ). These results suggest that targeting angiogenesis may potentially be protective against the incidence of CA.…”

Section: Discussionmentioning

confidence: 99%

Neuroimmune Responses in a New Experimental Animal Model of Cerebral Aspergillosis

Sullivan

Baggett

Guillory

et al. 2022

mBio

View full text Add to dashboard Cite

show abstract

“…There are other risk factors for invasive pulmonary aspergillosis such as neutropenia, haematological malignancy and corticosteroid therapy; however, they were not used in this study. The socio-demographic data, which include age, sex, occupation, residence, and medical history such as years on antiretroviral therapy and level of CD4 count were analysed as possible risk factors for IPA in this study but they were not statistically significant, although previous studies have shown that they could play a role in invasive pulmonary aspergillosis (10)(11)(12)(13)(14)(15)(16)(17)(18)(19).…”

Section: Relationship Between Risk Factors and Galactomannan Assay Seropositivitymentioning

confidence: 93%

“…The sample size for this study was derived using data from a cross-sectional study by Muzamil et al (10). Therefore, the minimum sample size required for this study was 95 using a 5% error margin and 95% confidence interval.…”

Section: Sample Size Calculationmentioning

confidence: 99%

Assessment of serum Aspergillus galactomannan expression and associated risk factors among patients living with HIV at Ilorin, Nigeria

et al. 2019

View full text Add to dashboard Cite

Invasive pulmonary aspergillosis still constitutes a diagnostic challenge for clinicians due to its non-specific symptoms. HIV infection represents one of the major risk factors due to the progressive failure of the immune system. In this study, Aspergillus serum galactomannan enzyme linked immunosorbent assay was used for the diagnosis of invasive pulmonary aspergillosis in patients living with HIV/AIDS attending University of Ilorin Teaching Hospital Antiretroviral Therapy Clinic, Nigeria. Blood samples were collected from 97 patients affected by HIV/AIDS. Age range of the study population was between 0 and 79 years. Length of the study: 3 weeks. Three out of the 97 samples were positive for the galactomannan assay with an optical density index of 1.1, 0.9 and 1.1 using the 0.5 cut-off optical density value; the concentration level of galactomannan antigen was therefore 2.20 μg/L, 1 μg/L and 2.19 μg/L, respectively. A prevalence of 3.1 % (3/97) was detected; all positive participants have been on ART for more than 3 years (P<0.0001), and 2 out of the 3 had CD4 count higher than 200 cells/mm3 (P<0.0001). Serum Aspergillus galactomannan assay is less invasive for patients and diagnosis can be made in a relatively shorter time compared to other techniques used in diagnosing invasive pulmonary aspergillosis.

show abstract

Invasive pulmonary aspergillosis in oncological setting with use of newer vascular endothelial growth factor receptor inhibitor

Cited by 3 publications

References 2 publications

Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India

Emergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India

Neuroimmune Responses in a New Experimental Animal Model of Cerebral Aspergillosis

Assessment of serum Aspergillus galactomannan expression and associated risk factors among patients living with HIV at Ilorin, Nigeria

Contact Info

Product

Resources

About